Anbio Biotechnology (NNNN)

Market Cap	248.86M
Revenue (ttm)	9.50M
Net Income (ttm)	4.33M
Shares Out	43.89M
EPS (ttm)	0.10
PE Ratio	55.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,412
Open	5.61
Previous Close	5.67
Day's Range	5.61 - 5.72
52-Week Range	5.18 - 5.89
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NNNN

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter utilization, point-of-care settings, and laboratory applications. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 19, 2025
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: NNNN

Financial Performance

In 2023, Anbio Biotechnology's revenue was $6.71 million, a decrease of -71.49% compared to the previous year's $23.54 million. Earnings were $2.25 million, a decrease of -77.49%.

Financial numbers in USD